Accessibility StatementSkip Navigation Dosed the First Patient in the 8-Week 48 mg MAD Cohort of its Phase 1 Clinical Trial to Further Explore Non- Titrated Maximum Tolerated Dose of DA-1726 for the Treatment of Obesity; Top-Line Data Expected by Year- End 2025 $14.3 Million in Cash at  End of Third Quarter is E xpected to Fund the Company Into 2026 CAMBRIDGE, Mass., Nov. 6, 2025 /PRNewswire/ -- MetaVia Inc. (Nasdaq: MTVA), a clinical-stage biotechnology company focused on transforming cardiometabolic d ...

Accessibility StatementSkip Navigation SALT LAKE CITY, Nov. 6, 2025 /PRNewswire/ -- Lipocine Inc. (NASDAQ: LPCN), a biopharmaceutical company leveraging its proprietary technology platform to augment therapeutics through effective oral delivery, today announced financial results for the third quarter ended September 30, 2025 and provided a corporate update. Neuroactive Steroids (NAS) LPCN 1154 for Postpartum Depression (PPD) LPCN 2101 for Epilepsy LPCN 2401 for Obesity Management TLANDOâ"¢ Lipocine has an ...

Accessibility StatementSkip Navigation CAPLYTA, in combination with an oral antidepressant, demonstrated superior efficacy with a favorable safety and tolerability profile consistent with established indications In pivotal trials, CAPLYTA did not increase mean weight gain, metabolic changes, or reported sexual side effects Experience the full interactive Multichannel News Release here: https://www.multivu.com/johnson-and- johnson/9355651-en-johnson-and-johnson-fda-approval-caplyta-lumateperone MDD, or clini ...

Accessibility StatementSkip Navigation NEW YORK, Nov. 5, 2025 /PRNewswire/ -- Metsera, Inc. (NASDAQ: MTSR) ("Metsera" or the "Company") today issued the following statement in response to a ruling in the litigation filed against the Company by Pfizer: "Metsera is gratified by the Delaware Court of Chancery's decision to deny Pfizer's request for a temporary restraining order to block Metsera's Board of Directors from acting in the best interests of shareholders. Separately, Pfizer has reiterated it will con ...

Accessibility StatementSkip Navigation Also from this source WASHINGTON, Nov. 5, 2025 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced that the company will participate in the Stifel 2025 Healthcare Conference in New York City on Wednesday, November 12, 2025. A corporate presentation is scheduled for 4:40 p.m. Eastern Time. The corporate presentation given at the Stifel conference may be accessed live on Vanda's corporate website, www.vandapharma.com. Investors should click ...

Accessibility StatementSkip Navigation THOUSAND OAKS, Calif., Nov. 4, 2025 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced financial results for the third quarter of 2025. Â "We delivered strong volume growth this quarter, reflecting the demand for our medicines and the impact we're having on patients worldwide. With disciplined investment and a pipeline of first-in-class medicines, we're focused on expanding access, advancing innovation, and sustaining long-term growth," said Robert A. Bradway, chairma ...

Accessibility StatementSkip Navigation SOUTH SAN FRANCISCO, Calif., Nov. 4, 2025 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL), a commercial stage biotechnology company focused on hematologic disorders and cancer, today reported financial results for the third quarter ended September 30, 2025, including sales of TAVALISSE (fostamatinib disodium hexahydrate), GAVRETO (pralsetinib) and REZLIDHIA (olutasidenib), and recent business progress. "Our strong third-quarter performance demonstrates ou ...

Accessibility StatementSkip Navigation Novo Nordisk Amended Proposal Values Metsera at up to $ 86.20 per Share, a Total of Approximately $ 10.0 Billion Pfizer Merger Agreement Remains in Effect; No Action Required by Metsera Shareholders Superior to Revised Pfizer Proposal that Valued Metsera at up to $ 70.00 per Share, a Total of Approximately $ 8.1 Billion Pursuant to Pfizer Merger Agreement, Metsera and Pfizer May Negotiate Potential Adjustments for Two Business Days NEW YORK, Nov. 4, 2025 /PRNewswire/ - ...

"Each study we present at Kidney Week is a piece of a larger puzzle, helping translate complex data into actionable insights that our care teams can use to help make a tangible difference in patients' lives," Dr. Brunelli shared. "This isn't research for the sake of research — it's about challenging norms, closing gaps and accelerating the pace of change in kidney care." Accessibility StatementSkip Navigation Six new studies from DaVita Clinical Research spotlight improved outcomes with GLP-1 use, advancem ...

Accessibility StatementSkip Navigation Financial results to be released after market close;Â Conference call to be conducted at 5:00 p.m. Eastern time PHOENIX, Nov. 3, 2025 /PRNewswire/ -- SenesTech, Inc. (NASDAQ: SNES), the leader in fertility control for pest management, will report third quarter 2025 financial results for the period ended September 30, 2025, after the market close on Monday, November 10, 2025. The Company has scheduled a conference call that same day, Monday, November 10, 2025, at 5:00 p ...